Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 4
2000 2
2001 5
2002 6
2003 9
2004 12
2005 15
2006 13
2007 8
2008 4
2009 10
2010 8
2011 8
2012 9
2013 1
2014 7
2015 2
2016 1
2017 3
2021 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 19443414

116 results

Results by year

Filters applied: . Clear all
Page 1
A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N, Kouroussis Ch, Papakotoulas P, Kalbakis K, Tryfonidis K, Vardakis N, Poppis E, Georgoulias V, Mavroudis D. Karachaliou N, et al. Cancer Chemother Pharmacol. 2012 May;69(5):1345-52. doi: 10.1007/s00280-012-1824-z. Epub 2012 Feb 17. Cancer Chemother Pharmacol. 2012. PMID: 22349809 Clinical Trial.
Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Murialdo R, Bertolotti F, Pastorino G, Mencoboni M, Bergaglio M, Folco U, Cinzia N, Vaira F, Simoni C, Canobbio L, Parodi M, Brema F, Ballestrero A. Murialdo R, et al. Cancer Chemother Pharmacol. 2011 Oct;68(4):1009-16. doi: 10.1007/s00280-011-1570-7. Epub 2011 Feb 16. Cancer Chemother Pharmacol. 2011. PMID: 21327683 Clinical Trial.
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Mavroudis D, Malamos N, Alexopoulos A, Kourousis C, Agelaki S, Sarra E, Potamianou A, Kosmas C, Rigatos G, Giannakakis T, Kalbakis K, Apostolaki F, Vlachonicolis J, Kakolyris S, Samonis G, Georgoulias V. Mavroudis D, et al. Ann Oncol. 1999 Feb;10(2):211-5. doi: 10.1023/a:1008315723253. Ann Oncol. 1999. PMID: 10093691 Free article. Clinical Trial.
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
Morabito A, Filippelli G, Palmeri S, Cascinu S, Ferraù F, Zagonel V, Gattuso D, Catalano V, Capaccetti B, Franciosi V, Accurso V, Scinto F, Gasparini G. Morabito A, et al. Breast Cancer Res Treat. 2003 Mar;78(1):29-36. doi: 10.1023/a:1022197109592. Breast Cancer Res Treat. 2003. PMID: 12611454 Clinical Trial.
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
Pelegrí A, Calvo L, Antón A, Mayordomo JI, Florián J, Vásquez S, Arcusa A, Martín-Richard M, Bayo JL, Carrasco E, Virizuela J; Spanish Group for Breast Cancer Research (GEICAM). Pelegrí A, et al. Clin Breast Cancer. 2005 Dec;6(5):433-8. doi: 10.3816/cbc.2005.n.048. Clin Breast Cancer. 2005. PMID: 16381627 Clinical Trial.
Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
Schmid P, Krocker J, Jehn C, Michniewicz K, Lehenbauer-Dehm S, Eggemann H, Heilmann V, Kümmel S, Schulz CO, Dieing A, Wischnewsky MB, Hauptmann S, Elling D, Possinger K, Flath B. Schmid P, et al. Ann Oncol. 2005 Oct;16(10):1624-31. doi: 10.1093/annonc/mdi321. Epub 2005 Jul 19. Ann Oncol. 2005. PMID: 16030028 Free article. Clinical Trial.
116 results